Home
Storia in 2 fonti
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
- ·
endpoints.news
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as…
- ·
biopharmadive.com
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.